BRADFORD BERK, MD
Osteopathic Medicine at Elmwood Ave, Rochester, NY

2008010, May 1, 2008

Nov 8, 2005

11/718677

Bradford Berk - Rochester NY, US
Jun-ichi Abe - Pittsford NY, US

UNIVERSITY OF ROCHESTER - Rochester NY

A01K 67/00, C12N 5/06, C12N 15/00, A61K 47/00, C12Q 1/02, G01N 33/53, C12N 15/11, C12N 1/20, C12N 7/00, G01N 33/573

800 3, 800 13, 800 18, 435325, 800 25, 514789, 435 29, 435 721, 800 9, 536 232, 4353201, 4352523, 4352351, 435 74

The present invention relates to a nucleic acid molecule encoding a K94A/K447A mutant of wild type p90 ribosomal S6 kinase (p90RSK) and DNA constructs, expression vectors, and hosts including the mutant p90RSK-encoding molecule. The present invention also relates to two transgenic non-human animal models of ischemic reperfusion (I/R) damage, the first animal having a transgene encoding a mutant p90RSK that is rendered kinase inactive for S703 phosphorylation of NHE1 and the second animal having a transgene encoding for cardiac-specific overexpression of wild type p90RSK in the animal that provides a model for diabetic cardiomyopathy. Also provided are methods for generating transgenic non-human animal models of ischemic reperfusion (I/R) damage; for using the transgenic cells for identifying an agent capable of inhibiting p90RSK-induced I/R damage; for identifying agents that modulate I/R injury resulting from an ischemic event; and for treating individuals to inhibit I/R injury following an ischemic event.

2010022, Sep 2, 2010

Sep 16, 2008

12/678352

Chen Yan - Rochester NY, US
Jian-Dong Li - Pittsford NY, US
Bradford Berk - Rochester NY, US
Xiangbin Xu - Rochester NY, US

UNIVERSITY OF ROCHESTER - Rochester NY

A61K 9/14, A61P 29/00, A61P 9/10, A61P 17/06, A61P 19/02, A61P 3/10, A61K 31/573, A61K 31/4375

424484, 514171, 514283

Pharmaceutical compositions and methods for treating or preventing an inflammatory condition in a patient are disclosed. The pharmaceutical compositions and methods include the use of vincamine or a vincamine derivative, either alone or in combination with one or more additional therapeutic agents, including a steroid (preferably a corticosteroid), an angiotensin II receptor (type 1) antagonist, an angiotensin-converting enzyme (ACE) inhibitor, and a non-steroidal anti-inflammatory drug.

2011009, Apr 28, 2011

Jan 20, 2006

11/814442

Bradford C. Berk - Rochester NY, US

UNIVERSITY OF ROCHESTER - Rochester NY

A61K 39/395, G01N 33/566, C12Q 1/02, G01N 33/53, C12Q 1/68, A61K 38/02

4241301, 436501, 435 29, 435 71, 435 792, 435 6, 514 19, 514 164

The present invention relates to screening assays for the identification of agents that can modify the interaction of thioredoxin interacting protein (TXNEP) on thioredoxin (TRX)5 preferably by inhibiting TXNIP downregulation of TXR. The use of such compounds, including the disclosed siRNA and antibodies against TXNIP, is contemplated for therapeutic or prophylactic treatment of vascular disease conditions, particularly those associated with pro-inflammatory activity of the TNF- ASK1-JNK-p38 pathways.